StreetInsider.com News Articles

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY.

The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archived for 90 days.

About

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY.
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archived for 90 days.
About

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY.
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archived for 90 days.
About

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 16:05:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 11:05am ET in New York, NY.
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website and will be archived for 90 days.
About

Savara presents biomarker data from phase 3 trial at ATS conference

Wed, 20 May 2026 08:15:18 -0400

Savara Inc. (NASDAQ: SVRA) presented biomarker data from its IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International Conference in Orlando. The study evaluated molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis.

The poster presentation reported data from the double-blind trial involving 164 patients who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. Researchers measured blood biomarker levels at baseline and at weeks 4, 12, 24, and 48.

Molgramostim demonstrated statistically significant improvements in pulmonary gas transfer compared to placebo at week 24 (P=0.0007) and week 48 (P=0.0008). Patients receiving molgramostim showed greater decreases

Savara presents biomarker data from phase 3 trial at ATS conference

Wed, 20 May 2026 08:15:18 -0400

Savara Inc. (NASDAQ: SVRA) presented biomarker data from its IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International Conference in Orlando. The study evaluated molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis.

The poster presentation reported data from the double-blind trial involving 164 patients who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. Researchers measured blood biomarker levels at baseline and at weeks 4, 12, 24, and 48.

Molgramostim demonstrated statistically significant improvements in pulmonary gas transfer compared to placebo at week 24 (P=0.0007) and week 48 (P=0.0008). Patients receiving molgramostim showed greater decreases

Savara presents biomarker data from phase 3 trial at ATS conference

Wed, 20 May 2026 08:15:18 -0400

Savara Inc. (NASDAQ: SVRA) presented biomarker data from its IMPALA-2 Phase 3 clinical trial at the American Thoracic Society International Conference in Orlando. The study evaluated molgramostim inhalation solution for treating autoimmune pulmonary alveolar proteinosis.

The poster presentation reported data from the double-blind trial involving 164 patients who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. Researchers measured blood biomarker levels at baseline and at weeks 4, 12, 24, and 48.

Molgramostim demonstrated statistically significant improvements in pulmonary gas transfer compared to placebo at week 24 (P=0.0007) and week 48 (P=0.0008). Patients receiving molgramostim showed greater decreases

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor

Wed, 20 May 2026 08:15:00 -0400

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
Below is a summary of the poster presented.
Poster Board 401: “Relationship Between Pulmonary Gas Transfer and Biomarker Levels in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP),” presented by Y. Inoue, M.D.; sponsored

Savara presents long-term data from molgramostim trial extension

Tue, 19 May 2026 14:15:14 -0400

Savara Inc. (NASDAQ: SVRA) presented long-term efficacy and safety data from the ongoing open-label extension of its IMPALA-2 Phase 3 clinical trial evaluating molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The IMPALA-2 trial enrolled 164 patients with autoimmune pulmonary alveolar proteinosis, making it the largest clinical trial conducted in the rare respiratory disease. During the double-blind period, patients received either nebulized molgramostim 300 µg or placebo once daily. All 160 patients who completed the double-blind period entered the open-label extension, where everyone receives molgramostim.

Data from the first 48 weeks of the 96-week open-label

Savara presents long-term data from molgramostim trial extension

Tue, 19 May 2026 14:15:14 -0400

Savara Inc. (NASDAQ: SVRA) presented long-term efficacy and safety data from the ongoing open-label extension of its IMPALA-2 Phase 3 clinical trial evaluating molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The IMPALA-2 trial enrolled 164 patients with autoimmune pulmonary alveolar proteinosis, making it the largest clinical trial conducted in the rare respiratory disease. During the double-blind period, patients received either nebulized molgramostim 300 µg or placebo once daily. All 160 patients who completed the double-blind period entered the open-label extension, where everyone receives molgramostim.

Data from the first 48 weeks of the 96-week open-label

Savara presents long-term data from molgramostim trial extension

Tue, 19 May 2026 14:15:14 -0400

Savara Inc. (NASDAQ: SVRA) presented long-term efficacy and safety data from the ongoing open-label extension of its IMPALA-2 Phase 3 clinical trial evaluating molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The IMPALA-2 trial enrolled 164 patients with autoimmune pulmonary alveolar proteinosis, making it the largest clinical trial conducted in the rare respiratory disease. During the double-blind period, patients received either nebulized molgramostim 300 µg or placebo once daily. All 160 patients who completed the double-blind period entered the open-label extension, where everyone receives molgramostim.

Data from the first 48 weeks of the 96-week open-label

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar

Tue, 19 May 2026 14:15:00 -0400

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 --
-- All Patients Receive Molgramostim During the OL Treatment Period; 100% of Patients Who Completed the Double-Blind (DB) Period of the Trial Entered into the OL Extension --
-- OL Data Showed Continued Improvement in Patients Who Had Received Molgramostim During DB Period --
-- Efficacy Improved in Patients Who Had Received Placebo During DB Period and Switched to Molgramostim in OL Treatment Period --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company

Savara reports improved exercise capacity in aPAP drug trial

Mon, 18 May 2026 14:55:16 -0400

Savara Inc. (NASDAQ: SVRA) presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The trial evaluated 164 adults with aPAP who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. The study had previously achieved statistical significance on its primary endpoint.

Patients receiving molgramostim walked an average of 167.0 meters more than baseline at week 48, compared to 86.4 meters for the placebo group, representing a treatment difference of 80.6 meters. The exercise duration improved by an average of

Savara reports improved exercise capacity in aPAP drug trial

Mon, 18 May 2026 14:55:16 -0400

Savara Inc. (NASDAQ: SVRA) presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The trial evaluated 164 adults with aPAP who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. The study had previously achieved statistical significance on its primary endpoint.

Patients receiving molgramostim walked an average of 167.0 meters more than baseline at week 48, compared to 86.4 meters for the placebo group, representing a treatment difference of 80.6 meters. The exercise duration improved by an average of

Savara reports improved exercise capacity in aPAP drug trial

Mon, 18 May 2026 14:55:16 -0400

Savara Inc. (NASDAQ: SVRA) presented new exercise capacity data from its IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis at the American Thoracic Society International Conference.

The trial evaluated 164 adults with aPAP who received either nebulized molgramostim 300 µg or placebo once daily for 48 weeks. The study had previously achieved statistical significance on its primary endpoint.

Patients receiving molgramostim walked an average of 167.0 meters more than baseline at week 48, compared to 86.4 meters for the placebo group, representing a treatment difference of 80.6 meters. The exercise duration improved by an average of